StreetInsider.com News Articles

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis.

SEOUL, South Korea, May 21, 2026 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago, IL.

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making.

SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, presented six studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, California.

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Fri, 17 Apr 2026 15:00:00 -0400

Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice

Thu, 16 Apr 2026 08:00:00 -0400

Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026

SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.